- $40.73m
- $146.60m
- $83.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.49 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -194.9% | ||
| Return on Equity | -295.35% | ||
| Operating Margin | -322.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 3.66 | 3.6 | 29.5 | 83.81 | 261.75 | 260.37 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).
Directors
- Andrew Obenshain PRE (48)
- Gina Consylman CFO (49)
- Jessica Whitten CAO (45)
- Jason Cole OTH (49)
- Thomas Klima OTH (49)
- Elisabeth Leiderman DRC (44)
- Najoh Tita-reid DRC
- John Agwunobi IND (56)
- Mark Vachon IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 16th, 1992
- Public Since
- June 19th, 2013
- No. of Shareholders
- 8
- No. of Employees
- 248
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 9,790,070
- Address
- 455 Grand Union Boulevard, SOMERVILLE, 02145
- Web
- https://www.bluebirdbio.com/
- Phone
- +1 3394999300
- Contact
- Courtney O'Leary
- Auditors
- Ernst & Young LLP
Upcoming Events for BLUE
Q2 2025 bluebird bio Inc Earnings Release
Similar to BLUE
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the bluebird bio share price?
As of Today at 01:38 UTC, shares in bluebird bio are trading at $4.16. This share price information is delayed by 15 minutes.
How has the bluebird bio share price performed this year?
Shares in bluebird bio last closed at $4.16 and the price had moved by -77.21% over the past 365 days. In terms of relative price strength the bluebird bio share price has underperformed the S&P500 Index by -78.96% over the past year.
What are the analyst and broker recommendations for bluebird bio?
The overall consensus recommendation for bluebird bio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the bluebird bio dividend yield?
bluebird bio does not currently pay a dividend.
Does bluebird bio pay a dividend?
bluebird bio does not currently pay a dividend.
When does bluebird bio next pay dividends?
bluebird bio does not currently pay a dividend.
How do I buy bluebird bio shares?
To buy shares in bluebird bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of bluebird bio?
As of the previous close price of $4.16, shares in bluebird bio had a market capitalisation of $40.73m.
Where are bluebird bio shares listed?
Here are the trading details for bluebird bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BLUE
What kind of share is bluebird bio?
Based on an overall assessment of its quality, value and momentum bluebird bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a bluebird bio share price forecast for 2025?
The analyst consensus target price for shares in bluebird bio is $7.20. That is 73.08% above the last closing price of $4.16.
Analysts covering bluebird bio currently have a consensus Earnings Per Share (EPS) forecast of -$9.85 for the next financial year.
Find out moreWhat is the trend in the bluebird bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like bluebird bio. Over the past six months, its share price has underperformed the S&P500 Index by -54.35%.
As of the last closing price of $4.16, shares in bluebird bio were trading -57.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the bluebird bio PE Ratio?
The bluebird bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of bluebird bio?
bluebird bio's management team is headed by:
- Andrew Obenshain - PRE
- Gina Consylman - CFO
- Jessica Whitten - CAO
- Jason Cole - OTH
- Thomas Klima - OTH
- Elisabeth Leiderman - DRC
- Najoh Tita-reid - DRC
- John Agwunobi - IND
- Mark Vachon - IND